CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (1997)

No AccessJournal of UrologyClinical Urology: Original Articles1 Nov 1997CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA McClellan M. Walther, James C. Yang, Harvey I. Pass, W. Marston Linehan, and Steven A. Rosenberg McClellan M. WaltherMcClellan M. Walther , James C. YangJames C. Yang , Harvey I. PassHarvey I. Pass , W. Marston LinehanW. Marston Linehan , and Steven A. RosenbergSteven A. Rosenberg View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)64091-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We defined the outcome of a strategy using cytoreductive surgery before high dose interleukin-2 (IL-2) therapy in patients with metastatic renal cell carcinoma. Materials and Methods: During an 11-year period, 195 patients underwent cytoreductive surgery as preparation for high dose IL-2 based therapy. The renal primary and locoregional metastatic disease that could be safely resected was removed. Results: Because of the large size 176 of 195 renal tumors (90%) were resected through transabdominal incision and in 45 patients (23%) a second additional significant procedure was performed. Five cases (2.6%) were unresectable and 2 (1%) perioperative deaths occurred. After surgery 121 of 195 patients (62%) were eligible for treatment with high dose IL-2 based protocols. Overall response rate to IL-2 based protocols was 18%. Conclusions: Cytoreductive surgery can be performed safely in patients with metastatic renal cell carcinoma. Although the impact of cytoreductive surgery on response to immunotherapy remains undefined, this combination of primary debulking and systemic IL-2 can result in durable complete tumor regression in some patients with metastatic renal cell carcinoma. References 1 : Surgery for metastatic renal cell carcinoma. J. Urol.1967; 97: 973. Link, Google Scholar 2 : Is nephrectomy justified in patients with metastatic renal carcinoma. J. Urol.1975; 114: 27. Abstract, Google Scholar 3 : Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J. Urol.1990; 144: 614. Link, Google Scholar 4 : Cytoreductive surgery prior to interleukin-2 based therapy in patients with metastatic renal cell carcinoma. Urology1993; 42: 250. Google Scholar 5 : Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol.1989; 7: 1863. Google Scholar 6 : Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg.1989; 210: 474. Google Scholar 7 : Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J. Urol.1993; 150: 463. Link, Google Scholar 8 : Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol.1995; 154: 32. Link, Google Scholar 9 : The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J. Urol.1994; 152: 1399. Abstract, Google Scholar 10 : Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer1971; 28: 1165. Google Scholar 11 : Prognostic factors and value of adjunctive nephrectomy in patients with stage IV renal cell carcinoma. Urology1991; 37: 95. Google Scholar 12 : Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J. Urol.1991; 145: 938. Link, Google Scholar 13 : Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. J. Urol.1993; 150: 1384. Abstract, Google Scholar 14 : Phase II trial of highdose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. J. Natl. Cancer Inst.1990; 82: 143. Google Scholar 15 : Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma. Brit. J. Urol.1995; 75: 586. Google Scholar 16 : Interleukin-2: use in solid tumors. Stem Cells1993; 11: 26. Google Scholar 17 : Interferon therapy of metastatic renal cell cancer. Sem. Surg. Oncol.1988; 4: 199. Google Scholar 18 : Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy. Eur. Urol.1990; 18: 42. Google Scholar 19 : Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J. Urol.1995; 154: 35. Link, Google Scholar 20 : Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2. Amer. J. Med.1987; 83: 1016. Google Scholar 21 : Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J. Urol.1992; 147: 24. Link, Google Scholar 22 : Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann. Intern. Med.1988; 108: 518. Google Scholar 23 : A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Sem. Oncol.1993; 20: 16. Google Scholar 24 : Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J. Natl. Cancer Inst.1988; 80: 60. Google Scholar 25 : Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alfa 2a: clinical effects. J. Biol. Response Mod.1990; 9: 538. Google Scholar 26 : Immunotherapy for metastatic renal cell cancer: effect on the primary tumor. J. Immunother.1993; 13: 130. Google Scholar From the Urologic Oncology and Surgery Branches, National Cancer Institute, Bethesda, Maryland.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKanao K, Mizuno R, Kikuchi E, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J and Oya M (2008) Preoperative Prognostic Nomogram (Probability Table) for Renal Cell Carcinoma Based on TNM ClassificationJournal of Urology, VOL. 181, NO. 2, (480-485), Online publication date: 1-Feb-2009.Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant M, Matin S, Swanson D and Wood C (2007) Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma With Nonclear Cell HistologyJournal of Urology, VOL. 178, NO. 5, (1896-1900), Online publication date: 1-Nov-2007.FLANIGAN R, MICKISCH G, SYLVESTER R, TANGEN C, VAN POPPEL H and CRAWFORD E (2018) Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined AnalysisJournal of Urology, VOL. 171, NO. 3, (1071-1076), Online publication date: 1-Mar-2004.KREJCI K, MARKIEWICZ M and KWON E (2018) Immunotherapy for Urological MalignanciesJournal of Urology, VOL. 171, NO. 2, (870-876), Online publication date: 1-Feb-2004.VASSELLI J, YANG J, LINEHAN W, WHITE D, ROSENBERG S and WALTHER M (2018) LACK OF RETROPERITONEAL LYMPHADENOPATHY PREDICTS SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMAJournal of Urology, VOL. 166, NO. 1, (68-72), Online publication date: 1-Jul-2001.FUJIKAWA K, MATSUI Y, MIURA K, KOBAYASHI T, OKA H, FUKUZAWA S and TAKEUCHI H (2018) SERUM IMMUNOSUPPRESSIVE ACIDIC PROTEIN AND NATURAL KILLER CELL ACTIVITY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA BEFORE AND AFTER NEPHRECTOMYJournal of Urology, VOL. 164, NO. 3 Part 1, (673-675), Online publication date: 1-Sep-2000.MOTZER R and RUSSO P (2018) SYSTEMIC THERAPY FOR RENAL CELL CARCINOMAJournal of Urology, VOL. 163, NO. 2, (408-417), Online publication date: 1-Feb-2000.FUJIKAWA K, MATSUI Y, OKA H, FUKUZAWA S and TAKEUCHI H (2018) SERUM C-REACTIVE PROTEIN LEVEL AND THE IMPACT OF CYTOREDUCTIVE SURGERY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAJournal of Urology, VOL. 162, NO. 6, (1934-1937), Online publication date: 1-Dec-1999.WAGNER J, WALTHER M, LINEHAN W, WHITE D, ROSENBERG S and YANG J (2018) INTERLEUKIN-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH THE KIDNEY IN PLACEJournal of Urology, VOL. 162, NO. 1, (43-45), Online publication date: 1-Jul-1999. (2018) EDITORIAL COMMENTJournal of Urology, VOL. 161, NO. 2, (386-387), Online publication date: 1-Feb-1999. Volume 158Issue 5November 1997Page: 1675-1678 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information McClellan M. Walther More articles by this author James C. Yang More articles by this author Harvey I. Pass More articles by this author W. Marston Linehan More articles by this author Steven A. Rosenberg More articles by this author Expand All Advertisement PDF downloadLoading ...